TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26178497

Group type: EXPERIMENTAL
Intervention: Cecal ligation puncture and rosiglitazone group (group CLP+ROSI)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Cecal ligation puncture group (group CLP)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Sham and rosiglitazone group (group Sham+ROSI)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Sham group (group Sham)
Number of subjects: 96
Study: 22692105

Group type: EXPERIMENTAL
Intervention: Warm-up program with functional exercises (WPS)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Warm-up program without functional exercises (NWP)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Change-of-direction sprints with functional exercises (WPS)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Change-of-direction sprints without functional exercises (NWP)
Number of subjects: 121
Study: 21375164

Group type: EXPERIMENTAL
Intervention: Manual vacuum aspiration (MVA)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Electrical vacuum aspiration (EVA)
Number of subjects: 176
Study: 18070234

Group type: EXPERIMENTAL
Intervention: FICE system with low magnification
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: FICE system with high magnification
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard colonoscopy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Conventional chromoendoscopy with indigo carmine
Number of subjects: 63
Study: 16313883

Group type: EXPERIMENTAL
Intervention: Therapist-initiated telephone sessions
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Therapist-initiated email sessions
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Client-initiated contact
Number of subjects: 100

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 100
Study: 15619967

Group type: EXPERIMENTAL
Intervention: Leucocyte filtration of residual heart-lung machine blood
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (unfiltered blood)
Number of subjects: 50
Study: 11086616

Group type: EXPERIMENTAL
Intervention: Abbreviated questionnaire
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Monetary incentive
Number of subjects: 146

Group type: COMPARATOR
Intervention: SF-36 Health Status Survey
Number of subjects: 146

Group type: COMPARATOR
Intervention: SF-36 plus a form assessing amount of treatment received
Number of subjects: 146
Study: 9352457

Group type: EXPERIMENTAL
Intervention: Multispectral maps
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional spin-echo images
Number of subjects: 16
Study: 1549886

Group type: EXPERIMENTAL
Intervention: Surgical suture and cast immobilisation for six weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cast immobilisation alone for six weeks
Number of subjects: 60
Study: 3903733

Group type: EXPERIMENTAL
Intervention: Diet and smoking advice
Number of subjects: 1232

Group type: EXPERIMENTAL
Intervention: Antismoking advice
Number of subjects: 1232
Study: 30463827

Group type: EXPERIMENTAL
Intervention: Xiaozhong Zhitong Decoction
Number of subjects: 160
Study: 26879829

Group type: EXPERIMENTAL
Intervention: Health literacy, quality of the provider interaction, perceived communication skills, and behavioral activation
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Quality of the provider interaction, perceived communication skills, and behavioral activation
Number of subjects: 109
Study: 23943112

Group type: EXPERIMENTAL
Intervention: Resistance training (ankle dorsiflexor muscles) three times per week for 2 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 23086244

Group type: EXPERIMENTAL
Intervention: Conventional management plus intravenous infusion of octreotide, 50 μg/h for 72 hours (obese-C+O)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Conventional management (obese-C)
Number of subjects: 243
Study: 20497150

Group type: EXPERIMENTAL
Intervention: GlideScope
Number of subjects: 42

Group type: COMPARATOR
Intervention: Direct laryngoscopy (Macintosh)
Number of subjects: 42
Study: 18568274

Group type: EXPERIMENTAL
Intervention: Community-based interventions delivered by lady health workers (LHWs) and traditional birth attendants (Dais) in intervention villages.
Number of subjects: 138600
Study: 15752371

Group type: EXPERIMENTAL
Intervention: Amyl nitrite (0.2 ml inhaled for 30 s)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (0.5 mg for 3 min)
Number of subjects: 21

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 21
Study: 12452302

Group type: EXPERIMENTAL
Intervention: Nicorandil (100 microg/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 24
Study: 10730758

Group type: EXPERIMENTAL
Intervention: VML 295 (LY-293111) 200 mg twice daily for 8 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: VML 295 (LY-293111)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 9377614

Group type: EXPERIMENTAL
Intervention: Mometasone furoate 0.1%-salicylic acid 5% ointment, applied twice daily for 21 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fluocinonide 0.05% ointment, applied twice daily for 21 days
Number of subjects: 40
Study: 1332095

Group type: EXPERIMENTAL
Intervention: Clonidine (2 micrograms/kg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 72
Study: 3873372

Group type: COMPARATOR
Intervention: Aspirin (3.9 g/day)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Aspirin (1.95 g/day) with Acetaminophen (1.95 g/day)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Aspirin (2.6 g/day) with Acetaminophen (2.6 g/day)
Number of subjects: 7
Study: 31640683

Group type: EXPERIMENTAL
Intervention: Poor patients
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Rich patients
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Patients without socio-economic markers
Number of subjects: 45
Study: 30342855

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU+)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside (SNP)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (HU-)
Number of subjects: 34
Study: 27255504

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including academic detailing, medicine review with web-based pharmaceutical treatment algorithms, and tailored patient information leaflets.
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Number of subjects: 196

Group type: COMPARATOR
Intervention: Usual care with simple, patient-level PIP feedback (Control)
Number of subjects: 196
Study: 24712840

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 22488488

Group type: EXPERIMENTAL
Intervention: Intervention arm with observed compliance during the trial and resumed population screening.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Contaminated control arm with observed contamination during the trial and resumed population screening.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uncontaminated control arm that discontinued screening upon entry.
Number of subjects: 0
Study: 20515625

Group type: EXPERIMENTAL
Intervention: Interventional training program for primary care physicians on beta-blocker use
Number of subjects: 627

Group type: COMPARATOR
Intervention: Control group (no training program)
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Interventional training group
Number of subjects: 627
Study: 18931880

Group type: EXPERIMENTAL
Intervention: Comprehensive postoperative rehabilitation program for women undergoing SNB
Number of subjects: 89

Group type: COMPARATOR
Intervention: No rehabilitation for women undergoing SNB
Number of subjects: 89

Group type: COMPARATOR
Intervention: Women undergoing ALND
Number of subjects: 89
Study: 15781762

Group type: EXPERIMENTAL
Intervention: Budesonide, 32 mug/d per nostril
Number of subjects: 61

Group type: COMPARATOR
Intervention: Desloratadine, 5 mg/d
Number of subjects: 61
Study: 12540404

Group type: EXPERIMENTAL
Intervention: Dual-fortified salt (DFS) containing 25 micro g iodine/g salt and 1 mg iron/g salt
Number of subjects: 377

Group type: COMPARATOR
Intervention: Iodized salt
Number of subjects: 377
Study: 10650538

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (two standard cigarettes)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham smoking
Number of subjects: 24
Study: 8707361

Group type: EXPERIMENTAL
Intervention: Amphotericin B (AMB) 1 mg/kg bw/day for 20 days
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Amphotericin B (AMB) 0.75 mg/kg bw/day for 20 days
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Amphotericin B (AMB) 0.5 mg/kg bw/day for 20 days
Number of subjects: 288
Study: 30355551

Group type: EXPERIMENTAL
Intervention: eHealth intervention-only
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: eHealth intervention-occupational physician
Number of subjects: 82

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 82
Study: 26967690

Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg daily) for 6 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 17
Study: 24655490

Group type: EXPERIMENTAL
Intervention: 2 green kiwifruit a day plus a healthy diet
Number of subjects: 85

Group type: COMPARATOR
Intervention: Healthy diet alone
Number of subjects: 85
Study: 22420776

Group type: COMPARATOR
Intervention: One-step self-etch adhesive systems (Clearfil S(3) Bond, AdheSE One, Adper Easy One) with aging condition 24 h in water (Control)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: One-step self-etch adhesive systems (Clearfil S(3) Bond, AdheSE One, Adper Easy One) with aging condition 6 months of water storage (WS)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: One-step self-etch adhesive systems (Clearfil S(3) Bond, AdheSE One, Adper Easy One) with aging condition 10,000 thermocycles (TC)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Clearfil S(3) Bond
Number of subjects: 72
Study: 20631413

Group type: EXPERIMENTAL
Intervention: 5 weeks of moderate-intensity endurance training
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 12
Study: 16516511

Group type: EXPERIMENTAL
Intervention: Loratadine (10mg daily)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Montelukast (10mg daily)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 16269590

Group type: EXPERIMENTAL
Intervention: TIMI flow grade <= 1
Number of subjects: 118

Group type: COMPARATOR
Intervention: TIMI flow grade > 1
Number of subjects: 118
Study: 12011706

Group type: EXPERIMENTAL
Intervention: Pneumatic compression
Number of subjects: 50

Group type: COMPARATOR
Intervention: No pneumatic compression (control)
Number of subjects: 50
Study: 10214571

Group type: EXPERIMENTAL
Intervention: ADCON‐L
Number of subjects: 298

Group type: COMPARATOR
Intervention: Control
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 298
Study: 7793992

Group type: COMPARATOR
Intervention: Radical esophagectomy with lower mediastinal and abdominal lymphadenectomy (Group A, n = 39)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Radical esophagectomy with incomplete 2-field dissection (Group B, n = 94)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Radical esophagectomy with extended cervicothoraco-abdominal lymph node dissection (3-field dissection) (Group C)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Radical esophagectomy with 3-field dissection (Group D)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Complete 2-field dissection
Number of subjects: 403

Group type: COMPARATOR
Intervention: 3-field dissection
Number of subjects: 403

Group type: COMPARATOR
Intervention: 2-field or 3-field dissection in cases with 7 or more positive lymph node metastases
Number of subjects: 403
Study: 1977089

Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg nocte
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg b.d.
Number of subjects: 230

Group type: COMPARATOR
Intervention: Ranitidine 150 mg b.d.
Number of subjects: 230

Group type: COMPARATOR
Intervention: Ranitidine 300 mg nocte
Number of subjects: 230
Study: 341950

Group type: EXPERIMENTAL
Intervention: mianserin 60 mg daily
Number of subjects: 54

Group type: COMPARATOR
Intervention: imipramine 150 mg daily
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: mianserin
Number of subjects: 54

Group type: COMPARATOR
Intervention: imipramine
Number of subjects: 54
Study: 31886693

Group type: EXPERIMENTAL
Intervention: Decision aid with educational information about newborn genomic sequencing and a values clarification exercise
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Decision aid with educational information about newborn genomic sequencing
Number of subjects: 1000
Study: 31527377

Group type: EXPERIMENTAL
Intervention: Bifiprost® + Serenoa Repens 320 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Serenoa Repens 320 mg alone
Number of subjects: 120
Study: 27788498

Group type: EXPERIMENTAL
Intervention: Irinotecan plus cisplatin (IP) followed by octreotide long-acting release (LAR) maintenance treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Irinotecan plus cisplatin (IP) followed by octreotide LAR maintenance treatment in high proliferation NET group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Irinotecan plus cisplatin (IP) followed by octreotide LAR maintenance treatment in poorly differentiated NEC (PDNEC) group
Number of subjects: 40
Study: 26718296

Group type: EXPERIMENTAL
Intervention: Neem containing toothpaste
Number of subjects: 30
Study: 23910702

Group type: EXPERIMENTAL
Intervention: Checklist intervention
Number of subjects: 48
Study: 22194781

Group type: EXPERIMENTAL
Intervention: Quality and Outcomes Framework (QOF) pay-for-performance programme
Number of subjects: 0
Study: 19076535

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 399

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study: 16737936

Group type: EXPERIMENTAL
Intervention: 900 mg of oral valganciclovir
Number of subjects: 22

Group type: COMPARATOR
Intervention: 5 mg/kg of intravenous ganciclovir
Number of subjects: 22
Study: 15218993

Group type: EXPERIMENTAL
Intervention: Tiotropium-AM
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Tiotropium-PM
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Tiotropium pooled
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 10926890

Group type: EXPERIMENTAL
Intervention: Computer program for interpreting consecutive measurements of cancer markers (CA 15.3, CEA, TPA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computer program for monitoring tumor marker measurements
Number of subjects: 0
Study: 9495661

Group type: EXPERIMENTAL
Intervention: Diastolic BP levels < or =90 mmHg
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: Diastolic BP levels < or =85 mmHg
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: Diastolic BP levels < or =80 mmHg
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: All target groups
Number of subjects: 922
Study: 8455128

Group type: EXPERIMENTAL
Intervention: Worth four‐dot (W4D) test
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Polarized four‐dot (P4D) test
Number of subjects: 107
Study: 3527086

Group type: EXPERIMENTAL
Intervention: Azathioprine (1 mg/kg for the first month, 2 mg/kg for the second month)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 28277811

Group type: EXPERIMENTAL
Intervention: Perceptual-motor intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stochastic vibration plus perceptual-motor intervention
Number of subjects: 0
Study: 25920707

Group type: EXPERIMENTAL
Intervention: Multidisciplinary Intervention (MI)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Brief Intervention (BI)
Number of subjects: 284
Study: 25424809

Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine with prophylactic paracetamol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine without prophylactic paracetamol
Number of subjects: 0

Group type: COMPARATOR
Intervention: MenC vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Routine infant vaccines (DTaP-HBV-IPV/Hib and PCV7) with 4CMenB
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine infant vaccines (DTaP-HBV-IPV/Hib and PCV7) with MenC
Number of subjects: 0
Study: 23706291

Group type: EXPERIMENTAL
Intervention: Nerve lateralization (NL)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nerve transposition (NT)
Number of subjects: 21
Study: 19874395

Group type: COMPARATOR
Intervention: Donepezil
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Donepezil and Memantine
Number of subjects: 63
Study: 18992601

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 16118355

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham manipulative treatment
Number of subjects: 31
Study: 12114877

Group type: EXPERIMENTAL
Intervention: Deep injection of radiotracer (group B)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Superficial injection of radiotracer (group A)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Deep injection of radiotracer (in outer quadrant patients)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Radioguided IMC biopsy
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Biopsy of axillary plus IMC nodes
Number of subjects: 400
Study: 9923808

Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 60
Study: 7757308

Group type: EXPERIMENTAL
Intervention: Nimodipine (30 mg t.i.d.)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nimodipine (30 mg t.i.d.) with Propranolol (40 mg t.i.d.)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Propranolol (40 mg t.i.d.)
Number of subjects: 24
Study: 11527140

Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg/day
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg/day
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Bisoprolol 10 mg/day
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Mepindolol 10 mg/day
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo (1-month run-in period)
Number of subjects: 129
Study: 6271381

Group type: EXPERIMENTAL
Intervention: CVVP-AD regimen (cyclophosphamide, VP-16, vincristine, cisplatin alternating with doxorubicin and DTIC)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: AVVP-CD regimen (doxorubicin, VP-16, vincristine, and cisplatin alternating with cyclophosphamide and DTIC)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Combined results of both regimens
Number of subjects: 66

Group type: COMPARATOR
Intervention: Prognostic variables
Number of subjects: 66

Group type: COMPARATOR
Intervention: CNS metastases
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sites of disease progression
Number of subjects: 66
Study: 30070034

Group type: EXPERIMENTAL
Intervention: Micro-needle mesotherapy with 20% L-ascorbic acid serum
Number of subjects: 17

Group type: COMPARATOR
Intervention: No-needle mesotherapy with 20% L-ascorbic acid serum
Number of subjects: 17
Study: 31411375

Group type: EXPERIMENTAL
Intervention: Community-based nurse-led lifestyle-modification intervention
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study: 29161260

Group type: EXPERIMENTAL
Intervention: Delivery arm (direct distribution of an oral HIVST from the peer educator)
Number of subjects: 965

Group type: EXPERIMENTAL
Intervention: Coupon arm (a coupon for collection of an oral HIVST from a health clinic/pharmacy)
Number of subjects: 965

Group type: COMPARATOR
Intervention: Standard-of-care arm (standard HIV testing)
Number of subjects: 965

Group type: EXPERIMENTAL
Intervention: Delivery arm
Number of subjects: 965

Group type: EXPERIMENTAL
Intervention: Coupon arm
Number of subjects: 965

Group type: COMPARATOR
Intervention: Standard-of-care arm
Number of subjects: 965

Group type: EXPERIMENTAL
Intervention: Linkage to care in HIVST arms
Number of subjects: 965

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 965
Study: 25627884

Group type: EXPERIMENTAL
Intervention: Yakult® (Treatment A)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Batavito® (Treatment B)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Yakult® (Treatment C)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Batavito® (Treatment D)
Number of subjects: 10
Study: 22746245

Group type: EXPERIMENTAL
Intervention: Microdose lithium treatment (300 μg, administered once daily for 15 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified, but implied to be without lithium treatment)
Number of subjects: 0
Study: 21684478

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40mg for 8 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 50
Study: 18689695

Group type: EXPERIMENTAL
Intervention: Clinical variables (waist circumference, hypertension, smoking, family history of diabetes)
Number of subjects: 3817

Group type: EXPERIMENTAL
Intervention: Predictive equation including fasting glucose, waist circumference, smoking, and gamma-glutamyltransferase for men; fasting glucose, BMI, triglycerides, and family history of diabetes for women.
Number of subjects: 3817

Group type: EXPERIMENTAL
Intervention: TCF7L2 and IL6 deleterious alleles
Number of subjects: 3817
Study: 16468063

Group type: EXPERIMENTAL
Intervention: Arm stroke propelling efficiency (etaP)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Distance covered per stroke (Ds)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Shoulder-to-hand distance (l)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Energy cost of swimming (C)
Number of subjects: 63
Study: 12846597

Group type: EXPERIMENTAL
Intervention: Ximelagatran 24mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diclofenac 50mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam 0.1 mg/kg (IV infusion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nifedipine 60mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Melagatran (active form of ximelagatran)
Number of subjects: 0